Dehydrodivanillin is a synthetic compound derived from vanillin. It is synthesized through the oxidative coupling of two vanillin molecules. Dehydrodivanillin has been investigated for its potential biological activities, including antioxidant, anti-inflammatory, and antimicrobial properties. It has also shown promise as a potential therapeutic agent in the treatment of various diseases, including cancer and Alzheimer's disease. Its unique structural features, including the presence of two vanillin moieties connected by a double bond, contribute to its biological activities. Research on dehydrodivanillin aims to understand its pharmacological mechanisms, optimize its synthesis, and explore its therapeutic applications.'
dehydrodivanillin: a lignin-related compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 95086 |
| CHEMBL ID | 41304 |
| SCHEMBL ID | 1487492 |
| MeSH ID | M0143566 |
| Synonym |
|---|
| [1,3'-dicarboxaldehyde, 6,6'-dihydroxy-5,5'-dimethoxy- |
| nsc-16723 |
| 5,5'-bivanillin |
| dehydrodivanillin |
| nsc16723 |
| 2092-49-1 |
| 3, 6,6'-dihydroxy-5,5'-dimethoxy- |
| CHEMBL41304 |
| 5,5-bisvanillin |
| 6,6'-dihydroxy-5,5'-dimethoxybiphenyl-3,3'-dicarbaldehyde |
| BMSE010019 |
| 3-(5-formyl-2-hydroxy-3-methoxyphenyl)-4-hydroxy-5-methoxybenzaldehyde |
| unii-29pyy1h4bt |
| nsc 16723 |
| 3,3'-biphenyldicarboxaldehyde, 6,6'-dihydroxy-5,5'-dimethoxy- |
| (1,1'-biphenyl)-3,3'-dicarboxaldehyde, 6,6'-dihydroxy-5,5'-dimethoxy- |
| 29pyy1h4bt , |
| FT-0688576 |
| S11876 |
| AKOS015889366 |
| 2,2'-dihydroxy-3,3'-dimethoxy-5,5'-diformylbiphenyl |
| 5,5'-diformyl-3,3'-dimethoxy-1,1'-biphenyl-2,2'-diol |
| fema no. 4107 |
| divanillin |
| divanillin [fhfi] |
| SCHEMBL1487492 |
| 6,6'-dihydroxy-5,5'-dimethoxy[1,1'-biphenyl]-3,3'-dicarbaldehyde # |
| [1,1'-biphenyl]-3,3'-dicarboxaldehyde, 6,6'-dihydroxy-5,5'-dimethoxy- |
| mfcd00156888 |
| 6,6'-dihydroxy-5,5'-dimethoxy-biphenyl-3,3'-dicarbaldehyde |
| [1,1'-biphenyl]-3,3'-dicarboxaldehyde,6,6'-dihydroxy-5,5'-dimethoxy- |
| A905938 |
| DS-10405 |
| EX-A4901 |
| Q27254436 |
| CS-0150461 |
| 6,6'-dihydroxy-5,5'-dimethoxy[1,1'-biphenyl]-3,3'-dicarbaldehyde |
| DTXSID30862830 |
| 6,6'-dihydroxy-5,5'-dimethoxy-[1,1'-biphenyl]-3,3'-dicarbaldehyde |
| 4-hydroxy-3-(2-hydroxy-5-methanoyl-3-methoxy-phenyl)-5-methoxy-benzaldehyde |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1306594 | Cytotoxicity against HMEC1 assessed as cell viability at 1 uM after 24 hrs by MTT assay in absence of oxidized LDL | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antioxidant phenolic diaryl hydrazones as potent antiangiogenic agents in atherosclerosis. |
| AID1306592 | Antioxidant activity in HMEC1 assessed as inhibition of cell induced LDL oxidation by measuring TBARS level at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antioxidant phenolic diaryl hydrazones as potent antiangiogenic agents in atherosclerosis. |
| AID1306590 | Antioxidant activity assessed as inhibition of DPPH free radical scavenging activity after 60 mins by UV-Visible spectrophotometry | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antioxidant phenolic diaryl hydrazones as potent antiangiogenic agents in atherosclerosis. |
| AID408062 | Protection against oxidized LDL-induced cytotoxicity in HMEC1 cells assessed as residual cell viability after 24 hrs by MTT assay relative to control | 2008 | Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11 | Development of novel antiatherogenic biaryls: design, synthesis, and reactivity. |
| AID407779 | Antioxidant activity in HMEC1 cells assessed as inhibition of LDL oxidation at 10 uM after 6 hrs by TBARS assay relative to control | 2008 | Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11 | Development of novel antiatherogenic biaryls: design, synthesis, and reactivity. |
| AID1306596 | Cytoprotective activity in HMEC1 assessed as inhibition of oxidized LDL induced toxicity measured as residual viability at 10 uM after 24 hrs by MTT assay (Rvb = 20 +/- 5 %) | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antioxidant phenolic diaryl hydrazones as potent antiangiogenic agents in atherosclerosis. |
| AID1306600 | Cytotoxicity against HMEC1 assessed as cell viability at 10 uM after 24 hrs by MTT assay in absence of oxidized LDL | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antioxidant phenolic diaryl hydrazones as potent antiangiogenic agents in atherosclerosis. |
| AID1306595 | Cytoprotective activity in HMEC1 assessed as inhibition of oxidized LDL induced toxicity measured as residual viability at 1 uM after 24 hrs by MTT assay (Rvb = 20 +/- 5 %) | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antioxidant phenolic diaryl hydrazones as potent antiangiogenic agents in atherosclerosis. |
| AID1306593 | Antioxidant activity in HMEC1 assessed as inhibition of cell induced LDL oxidation by measuring TBARS level at 10 uM relative to control | 2016 | Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16 | Synthesis and evaluation of antioxidant phenolic diaryl hydrazones as potent antiangiogenic agents in atherosclerosis. |
| AID222128 | Inhibition of proliferation in NCI panel of 60 human cell lines (Range is 20-80 uM) | 2000 | Journal of medicinal chemistry, Apr-20, Volume: 43, Issue:8 | Structural studies on bioactive compounds. 32. Oxidation of tyrphostin protein tyrosine kinase inhibitors with hypervalent iodine reagents. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (37.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.37) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||